Profusa to acquire PanOmics platform in $30M strategic pivot

Profusa (NASDAQ:PFSA) has entered into a non-binding letter of intent to acquire the PanOmics multi-omics diagnostics platform from BioInsights, a move that shifts the commercial-stage digital health company into the high-growth molecular diagnostics market.

The all-equity transaction is valued at approximately $30 million and is designed to integrate Profusa’s real-time biochemistry monitoring technology with BioInsights’ diagnostic capabilities.

The combination aims to establish a comprehensive franchise focused on biosensing, surgical monitoring, and precision medicine, specifically targeting complex indications such as pancreatic cancer.

Under the terms of the agreement, Profusa will acquire exclusive rights to the PanOmics platform and its associated intellectual property.

In exchange, BioInsights will receive roughly $30 million in Profusa equity securities and a 3% royalty on net revenue generated by the platform.

The deal is expected to add $30 million of shareholder equity to Profusa’s balance sheet, strengthening its financial position as it seeks additional capital to scale the new division.

The transaction includes provisions for BioInsights to nominate an independent member to Profusa’s board of directors.

Beyond technology transfer, BioInsights has committed to providing a specified number of samples for clinical validation, a critical step for accelerating the development of the company's pancreatic cancer diagnostic tools.

The proposed acquisition remains subject to the completion of due diligence, shareholder approval, and other customary closing conditions.